Summit Therapeutics SMMT Operating Lease Liabilities
Operating Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.
The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's operating lease liabilities?
- Summit Therapeutics (SMMT) reported operating lease liabilities of $16.86M in Q1 2026.
- How has Summit Therapeutics's operating lease liabilities changed year-over-year?
- Summit Therapeutics's operating lease liabilities increased by 479.9% year-over-year, from $2.91M to $16.86M.
- What is the long-term trend for Summit Therapeutics's operating lease liabilities?
- Over 5 years (2020 to 2025), Summit Therapeutics's operating lease liabilities has grown at a 197.6% compound annual growth rate (CAGR), from $75K to $17.5M.
- What does operating lease liabilities mean?
- The portion of lease payments due after more than one year.
- How do you interpret operating lease liabilities?
- High non-current lease liabilities indicate long-term commitments to physical infrastructure, which can be a sign of stability or a fixed cost burden.
- How does operating lease liabilities compare across companies?
- Reflects long-term operational strategy and facility footprint compared to industry peers.